文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

单日制备非活化IL-18武装CAR T细胞建立持久干样状态并增强存续

Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.
PubMed 文献 · Blood · 2026-01-01

该研究报道单日内生产分泌IL-18的非活化CART19细胞,在淋巴瘤、白血病和胰腺癌异种移植模型中显示强效抗肿瘤作用。IL-18表达增强非活化CAR T细胞的存续、代谢适应性和抗耗竭能力,单细胞转录组和代谢组分析揭示IL7R、KLF2、MCL1上调及PDCD1、TOX、HAVCR2抑制。该平台有望缩短静脉到静脉时间并提高产品效力与存续。

要点

  • 单日制备非活化IL-18分泌型CART19细胞可行
  • IL-18增强非活化CAR T细胞存续与抗耗竭
  • 多瘤种异种移植模型显示强效抗肿瘤活性

核心结论

  • 单日生产的非活化IL-18分泌型CAR T细胞建立持久干样状态并增强存续,支持临床测试。

研究设计与样本

  • 临床前研究,采用异种移植模型(淋巴瘤、白血病、胰腺癌)及体外功能、单细胞转录组和代谢组分析。

主要发现

  • 非活化CART19-IL-18细胞在淋巴瘤、白血病和胰腺癌异种移植模型中显示强效抗肿瘤疗效。
  • IL-18表达增强非活化CAR T细胞的存续、代谢适应性和抗耗竭能力。
  • 单细胞转录组显示IL7R、KLF2、MCL1上调,PDCD1、TOX、HAVCR2等抑制性检查点基因受抑制。
  • 代谢组显示线粒体生物能量增强,备用呼吸容量增加及α-酮戊二酸、苹果酸、精胺积累。

临床怎么用

  • 该平台可能缩短静脉到静脉时间并提高产品效力与存续,为标准化CAR T难治肿瘤患者提供临床测试依据。

局限性

  • 研究基于异种移植模型和体外分析,尚未在患者中验证临床疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single-day production of nonactivated CAR T cells engineered to secrete interleukin-18 (IL-18), a proinflammatory cytokine that enhances T-cell function. These nonactivated CART19-IL-18 cells (IL-18-secreting anti-CD19 CAR T cells) exhibit robust antitumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of naïve-like nonactivated CAR T cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of α-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18-enhanced, activation-free CAR T-cell product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T-cell therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Durgin JS, Seo S, Kazmi S, et al. Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence. Blood. 2026. PMID: 41990270. doi:10.1182/blood.2026033460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。